Anales de la RANM

251 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 PROTONTERAPIA CLÍNICA 2030 Calvo Manuel FA, et al. An RANM. 2023;140(03): 233 - 251 42. Huang D, Frank SJ, Verma V et al. Cost-effec- tiveness models of proton therapy for head and neck: Evaluating quality and methods to date. Int J Part Ther. 2021; 8(1): 339-353. doi: 10.14338/IJPT-20-00058.1 43. Bertagnolli MM, Carnival D, Jaffee EM. Achieving the goals of the cancer moons- hot requires progress against all cancers. Cancer Discov. 2023; 13(5): 1049-1052. doi: 10.1158/2159-8290.CD-23-0344 44. Yan S, Ngoma TA, Ngwa W, Bortfeld TR. Glo- bal democratisation of proton radiotherapy. Lancet Oncol. 2023; 24(6): e245-e254. doi: 10.1016/S1470-2045(23)00184-5 . 45. Prasanna PG, Rawojc K, Guha C, Buchsbaum JC, Miszczyk JU, Coleman CN. Normal tissue injury induced by photon and proton thera- pies: Gaps and opportunities. Int J Radiat On- col Biol Phys. 2021; 110(5): 1325-1340. doi: 10.1016/j.ijrobp.2021.02.043 46. Bekelman JE, Denicoff A, Buchsbaum J. Ran- domized trials of proton therapy: Why they are at risk, proposed solutions, and impli- cations for evaluating advanced technolo- gies to diagnose and treat cancer. J Clin On- col. 2018; 36(24): 2461-2464. doi: 10.1200/ JCO.2018.77.7078 47. Prasanna PGS, Narayanan D, Zhang K, Rahbar A, Coleman CN, Vikram B. Radiation biomarkers: Can small businesses drive ac- curate radiation precision medicine? Radiat Res. 2020; 193(3): 199-208. doi: 10.1667/ RR15553.1 48. Billay B, Wootten AC, Crowe H et al. The impact of multidisciplinary team mee- tings on patient´s assessment, management and outcomes in oncology settings: a sys- tematic review of the literature. Cancer Treat Rev. 2016; 42: 56-72. doi: 10.1016/j. ctrv.2015.11.007 49. Kroeze SGC, Pavic M, Stellamans K et al. Me- tastases-directed stereotactic body radiothe- rapy in combination with targeted therapy or immunotherapy: Systematic review and consensus recommendations by the EORTC- ESTRO OligoCare Consortium. Lancet Oncol. 2023; 24(3): e121-e132. doi: 10.1016/S1470- 2045(22)00752-5 50. Atun R, Jaffray DA, Barton MB et al. Expan- ding global access to radiotherapy. Lancet Oncol. 2015; 16(10): 1153-1186. doi: 10.1016/ S1470-2045(15)00222-3 . 51. Nogueira LM, Jemal A, Yabroff KR, Efstathiou JA. Assessment of proton beam therapy use among patients with newly diagnosed can- cer in the US, 2004-2018. JAMA Netw Open. 2022; 5(4): e229025. doi: 10.1001/jamanet- workopen.2022.9025 52. Goitein M, Cox JD. Should randomized clini- cal trials be required for proton radiotherapy? J Clin Oncol. 2008; 26(2): 175-176. doi: 10.1200/ JCO.2007.14.4329 53. Galluzzi L, Aryankalayil MJ, Coleman CN, Formenti SC. Emerging evidence for adapting radiotherapy to immunotherapy. Nat Rev Clin Oncol. 2023; 20(8): 543-557. doi: 10.1038/ s41571-023-00782-x . 54. Brenneman RJ, Sharifai N, Fischer-Valuck B et al. Abscopal effect following proton beam radiotherapy in a patient with inoperable me- tastatic retroperitoneal sarcoma. Front Oncol. 2019; 9: 922. doi: 10.3389/fonc.2019.00922 55. Calvo FA, Palma J, Serrano J et al. Hospital-ba- sed proton therapy implementation during the COVID pandemic: Early clinical and research experience in a European academic institution. Clin Transl Oncol. 2023; 25(5): 1268-1276. doi: 10.1007/s12094-023-03127-3 . Si desea citar nuestro artículo: Calvo Manuel FA, Gómez Caamaño A, Ferrer Albiach C, Rubio Ro- dríguez MC, Conde Moreno AJ, Giralt López de Sagredo J, Aris- tu Mendióroz J. Protonterapia y cáncer: horizonte clínico 2030 en España. An RANM. 2023;140(03): 233– 251. DOI: 10.32440/ ar.2023.140.03. rev01